Ensartinib (Ensacove™)

About Xcovery

Xcovery is a private, clinical-stage biotech founded in 2006 and headquartered in West Palm Beach, Florida. The company has built a pipeline of small molecule oncology drugs, led by ensartinib, an FDA-approved ALK inhibitor for non-small cell lung cancer (NSCLC), and vorolanib, a next-generation multi-kinase angiogenesis inhibitor in development. Xcovery operates with a lean model, seeking commercial partners for ensartinib and development partners for vorolanib combinations, while leveraging the expertise of a board with deep industry and development experience.

Therapeutic Areas